鼓室成形术联合咽鼓管球囊扩张术治疗慢性炎性中耳疾病:一项随机临床试验
这项平行组、单盲、单中心随机临床试验纳入76例慢性炎性中耳疾病伴咽鼓管功能障碍并计划行鼓室成形术的患者,比较单纯鼓室成形术与附加咽鼓管球囊扩张术(ETBD)的疗效。结果显示,在术后12个月内,两组咽鼓管评分(ETS)变化差值0.21(95%CI -1.17至1.59),排除3分及以上临床有意义差异;气骨导差(ABG)变化差值-2.8 dB(95%CI -9.1至3.5),ETDQ-7变化差值-0.2(95%CI -3.4至3.1)。结论认为,ETBD作为附加手术并未改善ETS、ABG或主观长期咽鼓管功能,不推荐常规附加使用。
要点
- 对于慢性炎性中耳疾病伴咽鼓管功能障碍行鼓室成形术者,附加ETBD未改善ETS。
- 附加ETBD未改善ABG或ETDQ-7评分,组间差异均未达统计学显著。
- 作者认为,该适应证下不应将ETBD作为鼓室成形术的常规附加手术。
核心结论
- 在慢性炎性中耳疾病伴咽鼓管功能障碍患者中,鼓室成形术附加ETBD未改善ETS、ABG或主观长期咽鼓管功能。
- 作者认为,该适应证下不应将ETBD作为鼓室成形术的常规附加手术。
- 作者指出,更大规模的多中心随机试验可提供更多关于ETBD疗效的见解,并允许进行特定亚组分析。
研究设计与样本
- 平行组、单盲、单中心随机临床试验,纳入2015年1月至2019年11月在一家三级转诊中心就诊并计划行鼓室成形术的慢性炎性中耳疾病伴咽鼓管功能障碍患者。
- 共76例随机分组,68例纳入意向性治疗分析;鼓室成形术组34例,鼓室成形术联合ETBD组34例。
- 数据于2022年6月至2023年12月进行分析;试验注册号:德国临床试验注册中心DRKS00031807。
主要发现
- 鼓室成形术组34例中女性20例(59%),平均(SD)年龄53.4(12.5)岁;鼓室成形术联合ETBD组34例中女性13例(38%),平均(SD)年龄51.4(14.5)岁。
- 术后12个月内,鼓室成形术组平均ETS变化1.62(95%CI 0.66-2.59),联合ETBD组1.41(95%CI 0.43-2.39),组间差值0.21(95%CI -1.17至1.59)。
- 上述结果排除了ETS存在3分及以上临床有意义差异的可能性。
- 术后12个月,鼓室成形术组ABG从26.1 dB改善至19.0 dB听力损失,联合ETBD组从30.1 dB改善至20.1 dB听力损失;组间ABG变化差值-2.8 dB(95%CI -9.1 dB至3.5 dB)。
- 两组平均ETDQ-7变化差值-0.2(95%CI -3.4至3.1)。
关键数值与推荐
- 主要结局为ETS变化;次要结局为ABG和ETDQ-7评分变化。
- ETS组间变化差值0.21(95%CI -1.17至1.59),排除3分及以上临床有意义差异。
- ABG组间变化差值-2.8 dB(95%CI -9.1 dB至3.5 dB)。
- ETDQ-7组间平均变化差值-0.2(95%CI -3.4至3.1)。
临床怎么用
- 作者认为,对于慢性炎性中耳疾病伴咽鼓管功能障碍行鼓室成形术的患者,不应将ETBD作为常规附加手术。
- 作者指出,更大规模的多中心随机试验可提供更多关于ETBD疗效的见解,并允许进行特定亚组分析。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Eustachian tube balloon dilation (ETBD) is increasingly used to treat Eustachian tube (ET) dysfunction, but its benefit in patients requiring tympanoplasty for chronic inflammatory middle ear disease is unclear. OBJECTIVE: To evaluate the efficacy of additional ETBD on the Eustachian Tube Score (ETS), hearing outcomes, and subjective ET function in patients with obstructive ET dysfunction undergoing tympanoplasty. DESIGN, SETTING, AND PARTICIPANTS: This parallel-group, single-blind, monocentric, randomized clinical trial included patients with chronic inflammatory middle ear disease and ET dysfunction seen at a tertiary referral center and scheduled for tympanoplasty between January 2015 and November 2019. Data were analyzed between June 2022 and December 2023. INTERVENTION: Patients were randomized to tympanoplasty only or an additional ETBD of the affected side. MAIN OUTCOMES AND MEASURES: The main outcome was the change in ETS, and secondary outcome measures were change in the air-bone gap (ABG) and Eustachian Tube Dysfunction Questionnaire (ETDQ-7) scores. RESULTS: From 76 randomized participants, 68 were included in the intention-to-treat analysis. Of the 34 patients in the tympanoplasty group, 20 participants (59%) were female, and the mean (SD) age was 53.4 (12.5) years. Of the 34 patients in the tympanoplasty plus ETBD group, 13 participants (38%) were female, and the mean (SD) age was 51.4 (14.5) years. During the first 12 months after the procedure, the difference in mean ETS changes between the tympanoplasty (1.62 [95% CI, 0.66-2.59]) and the tympanoplasty plus ETBD group (1.41 [95% CI, 0.43-2.39]) was 0.21 (95% CI, -1.17 to 1.59). These results rule out the possibility of a clinically meaningful difference of 3 points or more in ETS. Twelve months after the procedure, ABG improved from 26.1 dB to 19.0 dB hearing loss in the tympanoplasty group and from 30.1 dB to 20.1 dB hearing loss in the tympanoplasty plus ETBD group. The difference in ABG changes between the groups was -2.8 dB (95% CI, -9.1 dB to 3.5 dB), and the difference in mean ETDQ-7 changes was -0.2 (95% CI, -3.4 to 3.1). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, the addition of ETBD to tympanoplasty in patients with chronic inflammatory middle ear disease and ET dysfunction did not improve the outcome regarding ETS, ABG, or subjective long-term ET function. ETBD should, therefore, not be routinely performed as an add-on procedure to tympanoplasty for this indication. Larger multicentric randomized trials could provide more insights into the efficacy of ETBD in patients with chronic inflammatory middle ear disease undergoing tympanoplasty and would allow for specific subgroup analyses. TRIAL REGISTRATION: German Clinical Trials Register Identifier: DRKS00031807.
引用
- Gey A, Honeder C, Reiber J, et al. Tympanoplasty With Eustachian Tube Balloon Dilation for Chronic Inflammatory Middle Ear Disease: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2025. PMID: 40372749. doi:10.1001/jamaoto.2025.0904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。